Most patients with advanced prostate cancer (PCa) will develop metastatic castration-
resistant prostate cancer (mCRPC) after androgen deprivation therapy, at this time the tumor …

The ability to selectively target cancer cells makes antibody–drug conjugates (ADCs)
promising therapeutic options. They have been tested in clinical trials as a vehicle for tumor …

Conventional chemotherapy is insufficient for precise cancer treatment due to its lack of
selectivity and inevitable side effects. Targeted drugs have emerged as a promising solution …

Simple Summary Prostate-specific membrane antigen (PSMA)-targeting radioligands have
been used clinically to treat metastatic prostate cancer. To deliver a sufficient radiation dose …

The evolution of cancer therapies has highlighted the limitations of traditional chemotherapy,
particularly its lack of specificity and off-target toxicities, driving the development of targeted …

Recently, peptide-drug conjugate (PDC) has become the most promising conjugated drug
for tumor therapy after antibody-drug conjugate due to stronger tumor penetration capacity …

Small molecule drug conjugates are an emerging targeted therapy for cancer treatment.
Building upon the overexpressed prostate-specific membrane antigen (PSMA) in prostate …

In the aging global population, prostate cancer is a worldwide health problem because the
incidence rate of this disease increases at advanced ages. Although early-stage prostate …

This project describes the development of a new antitumor therapeutic platform that
combines the benefits of small-molecule drug conjugates (SMDCs) and antibody drug …